Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Amy Dobberfuhl, received a B.S. in Mechanical Engineering from North Carolina State University in 2004 and her M.D. from the University of North Carolina at Chapel Hill School of Medicine in 2010. She completed her residency training in Urology at Albany Medical College in New York in 2015. She then completed an ACGME fellowship in FPMRS (Female Pelvic Medicine & Reconstructive Surgery) with a special emphasis on Neurourology & Voiding Dysfunction, in the Department of Urology at Stanford University in 2017. Dr. Dobberfuhl was also awarded the KL2 component of the Stanford Clinical and Translation Science Award to Spectrum (NIH 5KL2TR001083) and completed an M.S. in Epidemiology and Clinical Research from Stanford University in 2018. Following fellowship in 2017 Dr. Dobberfuhl joined the Department of Urology and her practice includes both a clinical and research focus.<br/><br/>Dr. Dobberfuhl's current clinical practice includes: Pelvic Reconstruction, Neurourology, and Voiding Dysfunction. A large proportion of Dr. Dobberfuhl's Voiding Dysfunction practice includes Bladder Pain Syndrome (BPS) and Pelvic Floor Dysfunction (PFD).<br/><br/>Dr. Dobberfuhl’s basic science and clinical translational research focus includes: Animal models of voiding dysfunction and IC/BPS, Pelvic floor ischemia and effect of estrogen on lower urinary tract, Urinary biomarkers and molecular mechanisms implicated in lower urinary tract dysfunction (WHSDM). <br/><br/>Dr. Dobberfuhl’s clinical research focus includes: Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), Sex differences in lower urinary tract dysfunction, Radiation cystitis, Overactive (OAB) and Underactive Bladder (UAB).<br/><br/>Dr. Dobberfuhl's current IRB approved prospective clinical research for which she may invite her patients to enroll include:<br/><br/>1. WHSDM Study (Funding: Women's Health & Sex Differences in Medicine & NIH LRPCR 1L30DK115056-01). This is a prospective observational cohort of men and women enrolled by Dr. Dobberfuhl (PD/PI) and her collaborators (Dr. Bertha Chen, Dr. Elizabeth Kidd). The goal of this research is to study gender related differences in bladder function that occur in men and women with lower urinary tract dysfunction. The conditions we are studying in Aim 1 include: overactive bladder, underactive bladder, urinary retention, urgency incontinence, recurrent urinary tract infection (UTI), interstitial cystitis / bladder pain syndrome (IC/BPS), prostatitis, and radiation cystitis. In Aim 2 we assess changes in bladder function which occur over time in women with cervical or endometrial cancer treated with radiotherapy. Eligible women and men with the above conditions are invited to participate.<br/><br/>2. SUFU Clinical trial of transvaginal onabotulinumtoxinA for refractory overactive bladder (Funding: Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction). This is a SUFU Foundation investigator initiated clinical trial (PD/PI Dr. Dobberfuhl) of a novel approach to deliver botulinum toxin to the bladder without the need for a cystoscope, in women who have refractory overactive bladder (OAB). Eligible women who have failed 1st and 2nd line OAB treatment are invited to participate.<br/><br/>3. CYSTONET Study (Funding: National Institutes of Health, PI: Joseph Liao): Dr. Dobberfuhl is a co-investigator for an IRB approved study titled "Development of Cystoscopy Database for Bladder Disease Prediction" sponsored by a research grant from the NIH. Dr. Dobberfuhl is conducting Specific Aim 2: "To train CystoNet to identify flat bladder cancer including carcinoma in situ (CIS) while excluding cancer-mimicking benign bladder diseases". Dr. Dobberfuhl is enrolling patients with likely benign bladder disease for the CYSTONET cystoscopy neural network. Eligible women and men undergoing routine cystoscopy are invited to participate.